
|Articles|April 1, 2003
Psoriasis Drug MIA
San Francisco - The anti-CD40 ligand monoclonal antibody IDEC-131, manufactured by IDEC Pharmaceuticals, was developed to treat autoimmune and inflammatory diseases, such as psoriasis. IDEC-131 targets the CD40 ligand on T cells and regulates the interaction between T cells and B cells.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Lebrikizumab Enters Late-Stage Testing for Nummular Eczema
2
The Weekly Roundup: January 12-16
3
Subgroup Analysis Demonstrates Efficacy of Roflumilast Cream for AD in Pediatric Patients With Diverse Skin Types
4
Graham Heap, MBBS, PhD, Discusses Positive Phase 3 Results for Zasocitinib
5


















